Krystal Biotech, Inc. (KRYS)
359.36
+7.90
(+2.25%)
USD |
NASDAQ |
Aug 31, 16:00
359.37
+0.01
(+0.00%)
After-Hours: 20:00
Krystal Biotech Total Long Term Debt (Quarterly) : 7.045M for June 30, 2026
Total Long Term Debt (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Long Term Debt (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 7.045M |
| March 31, 2026 | 7.312M |
| December 31, 2025 | 7.568M |
| September 30, 2025 | 7.813M |
| June 30, 2025 | 8.064M |
| March 31, 2025 | 8.30M |
| December 31, 2024 | 6.044M |
| September 30, 2024 | 6.184M |
| June 30, 2024 | 6.326M |
| March 31, 2024 | 6.465M |
| December 31, 2023 | 6.62M |
| September 30, 2023 | 6.819M |
| June 30, 2023 | 7.014M |
| March 31, 2023 | 7.205M |
| December 31, 2022 | 7.372M |
| September 30, 2022 | 7.575M |
| June 30, 2022 | 7.716M |
| March 31, 2022 | 7.883M |
| December 31, 2021 | 6.983M |
| September 30, 2021 | 7.079M |
| June 30, 2021 | 6.897M |
| Date | Value |
|---|---|
| March 31, 2021 | 3.222M |
| December 31, 2020 | 3.308M |
| September 30, 2020 | 2.533M |
| June 30, 2020 | 2.618M |
| March 31, 2020 | 2.701M |
| December 31, 2019 | 2.782M |
| September 30, 2019 | 2.86M |
| June 30, 2019 | 2.926M |
| March 31, 2019 | 2.976M |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.00 |
| June 30, 2018 | 0.00 |
| March 31, 2018 | 0.00 |
| December 31, 2017 | 0.00 |
| September 30, 2017 | 0.00 |
| June 30, 2017 | 4.142M |
| March 31, 2017 | 2.143M |
| December 31, 2016 | 1.843M |
| September 30, 2016 | 0.00 |
| June 30, 2016 | 0.00 |
| March 31, 2016 | 0.00 |
Total Long Term Debt Definition
Represents a company's total debt maturing for more than 12 months of the reporting period.
Total Long Term Debt (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Long Term Debt (Quarterly) Benchmarks
| Marker Therapeutics, Inc. | 0.00 |
| TG Therapeutics, Inc. | 752.53M |
| Cytokinetics, Inc. | 1.250B |
| ADMA Biologics, Inc. | 202.66M |
| Alnylam Pharmaceuticals, Inc. | 2.942B |